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Paracrine inhibition of prion propagation by anti-PrP
single-chain Fv miniantibodies
Abstract
Prion diseases are characterized by the deposition of PrP(Sc), an abnormal form of the cellular prion
protein PrP(C). A growing body of evidence suggests that antibodies to PrP(C) can antagonize
deposition of PrP(Sc). However, host tolerance hampers the induction of immune responses to PrP(C),
and cross-linking of PrP(C) by bivalent anti-PrP antibodies is neurotoxic. In order to obviate these
problems, we explored the antiprion potential of recombinant single-chain antibody (scFv) fragments.
scFv fragments derived from monoclonal anti-PrP antibody 6H4, flagged with c-myc and His6 tags,
were correctly processed and secreted by mammalian RD-4 rhabdomyosarcoma cells. When cocultured
with cells secreting anti-PrP scFv, chronically prion-infected neuroblastoma cells ceased to produce
PrP(Sc), even if antibody-producing cells were physically separated from target cells in transwell
cultures. Expression of scFv with irrelevant specificity, or of similarly tagged molecules, was not
curative. Therefore, eukaryotically expressed scFv exerts a paracrine antiprion activity. The effector
functions encoded by immunoglobulin constant domains are unnecessary for this effect. Because of their
small size and their monovalent binding, scFv fragments may represent candidates for gene
transfer-based immunotherapy of prion diseases.
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Prion diseases are characterized by the deposition of PrPSc, an abnormal form of the cellular prion protein
PrPC. A growing body of evidence suggests that antibodies to PrPC can antagonize deposition of PrPSc.
However, host tolerance hampers the induction of immune responses to PrPC, and cross-linking of PrPC by
bivalent anti-PrP antibodies is neurotoxic. In order to obviate these problems, we explored the antiprion
potential of recombinant single-chain antibody (scFv) fragments. scFv fragments derived from monoclonal
anti-PrP antibody 6H4, flagged with c-myc and His6 tags, were correctly processed and secreted by mammalian
RD-4 rhabdomyosarcoma cells. When cocultured with cells secreting anti-PrP scFv, chronically prion-infected
neuroblastoma cells ceased to produce PrPSc, even if antibody-producing cells were physically separated from
target cells in transwell cultures. Expression of scFv with irrelevant specificity, or of similarly tagged molecules,
was not curative. Therefore, eukaryotically expressed scFv exerts a paracrine antiprion activity. The effector
functions encoded by immunoglobulin constant domains are unnecessary for this effect. Because of their small
size and their monovalent binding, scFv fragments may represent candidates for gene transfer-based immu-
notherapy of prion diseases.
Prion diseases, or transmissible spongiform encephalopa-
thies, are invariably lethal neurodegenerative illnesses that af-
fect humans and many animal species. They include bovine
spongiform encephalopathy of cattle, chronic wasting disease
of mule deer and elk, and Creutzfeldt-Jakob disease (CJD) in
humans (3). The causative agent is termed a prion (36) and was
proposed to be identical to PrPSc, a pathological conformer of
the cellular protein PrPc encoded by the Prnp gene (31). PrPC
is expressed on the surfaces of almost all cells in the body but
at particularly high levels on neurons in the peripheral and
central nervous systems. PrPC is essential for the development
of prion disease (7), and Prnpo/o mice, which lack PrPC, are
resistant to scrapie (8).
The bovine spongiform encephalopathy epidemic (42) can
be arguably deemed the direct consequence of flawed technol-
ogy assessment and is caused by prions that were amplified
through the bovine food chain (41). Transmission of bovine
prions to humans has then given rise to variant CJD (44). At
the time of this writing, Switzerland is experiencing an alarm-
ing increase in the incidence of a form of CJD which is clini-
cally and biochemically indistinguishable from sporadic CJD
and whose cause has not yet been conclusively determined (11,
12). Also, the recent increase in chronic wasting disease in
North America (38) underlines the fact that prion diseases of
farm and wildlife animals still represent a threat to public
health. For all the reasons enumerated above, there is an
urgent and growing need for efficient preventive and/or ther-
apeutic measures against prion diseases (2).
Prions use immune cells to gain access to the brain (14, 20,
35). On the other hand, several reports indicate that humoral
immune responses against the prion protein can antagonize
prion infections. This is true even when such responses are
directed primarily against PrPC and do not selectively target
the disease-associated prion protein, PrPSc. For example,
monoclonal antibodies directed against PrPC have been shown
to prevent de novo scrapie infection and to abrogate prion
infectivity and PrPSc from chronically scrapie-infected neuro-
blastoma cells (10, 33). Transgenic expression (16) or periph-
eral administration of anti-PrP antibodies in mice (43) can
arrest peripheral scrapie pathogenesis, and PrP-Fc fusion
molecules interfere with prion replication (30).
One major obstacle to devising efficacious regimens of active
immunization is host tolerance to endogenous PrPC that in-
hibits a host-derived anti-PrP antibody immune response. Ac-
tive immunization attempts have thus far resulted in the in-
duction of meager anti-PrP titers at best (13, 22, 34, 39).
Accordingly, the biological efficacy of these immunization se-
ries was limited (34, 39), emphasizing the need for alternative
strategies.
Conversely, administration of antibodies generated in Prnp-
ablated animals (“passive immunization”), while feasible and
effective (43), suffers from the intrinsic problem of poor diffu-
sion from vessels into tissues, particularly into the central ner-
vous tissue. This may explain why administration of monoclo-
nal antibodies has been shown to prevent prion pathogenesis
only when applied simultaneously or shortly after peripheral
prion infection (43). In addition, production of the large
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amounts of monoclonal antibodies necessary for the treatment
of human patients is technically challenging and expensive (18,
25, 28).
Delivery of antibodies by gene therapy may circumvent the
limitations described above by providing a steady, localized
supply of antibodies which obviates the need for repetitive
injections. However, whole antibodies are unwieldy and un-
dergo a complex biogenesis, and their large genes are poorly
suitable for efficient genetic transfer with vectors. Worryingly,
intracerebral injection of anti-PrP immunoglobulin G (IgG)
antibodies was found to provoke neurotoxicity by cross-linking
PrPC (40).
One possible solution to the latter problems is offered by the
use of phage display-based single-chain miniantibodies (scFvs),
which are small and consist of a single fusion polypeptide.
ScFvs are often derived from natural or synthetic cDNA librar-
ies, but they can also be engineered from the sequences en-
coding the variable regions of individual hybridomas. In the
latter case, scFvs retain the antigen binding properties of the
parent monoclonal antibody (19, 24, 26, 45). Here we tested a
novel strategy of paracrine immunization that employs soluble
scFvs with anti-PrP specificity. We find that secretion of anti-
PrP scFvs by mammalian cells cures chronically prion-infected
N2a neuroblastoma cells (ScN2a). These results suggest that
open reading frames (ORFs) encoding anti-PrP scFvs may be
used in gene therapy against prion diseases.
MATERIALS AND METHODS
Cell culture. The human rhabdomyosarcoma cell line RD-4 was obtained from
David Derse (National Cancer Institute, Frederick, Maryland) and cultured in
Dulbecco’s modified Eagle’s medium (Gibco) supplemented with 10% fetal calf
serum (Gibco). The chronically prion-infected mouse neuroblastoma cell line
N2a/Bos2 (10) was kindly provided by Charles Weissmann (London, United
Kingdom) and cultured in OPTI-MEM supplemented with 10% fetal calf serum
and penicillin G-streptomycin (Gibco) at 37°C in 5% CO2. Cells were grown in
10-cm dishes and routinely split 1:5 every 3 to 4 days.
Construction and selection of anti-PrP scFv fragment. RNA was prepared
from 6H4 hybridoma cell pellets (23), and cDNA was obtained by subsequent
reverse transcription-PCR. VH and VL fragments were amplified, joined by PCR
assembly, and cloned into the phage display vector pAK100 (19, 24) as described
previously (16). Functionality of phages displaying 6H4 single-chain antibodies
was analyzed in a standard enzyme-linked immunosorbent assay. The resulting
scFvs were amplified by PCR with the primers 5-GCC GTA CGA AGC TTG
ATG GCG GAC TAC AAA GAC ATT GTT-3 and 5-GGG CCC TCC TCG
AGC GAT CAG CTT CTG CTC GAA TTC GGC-3, introducing unique
HindIII and XhoI restriction sites (underlined) at the 5 and 3 ends, respec-
tively. The modified scFvs ORFs were cloned in frame into the plasmid vector
pSecTag2/HygroA (Invitrogen), resulting in the generation of pSecTag2/Hy-
gro4.1 and pSecTag2/Hygro4.5. RD-4 cells were transfected with 30 l of
GenePorter transfection reagent and 6 g of plasmid DNA in a six-well plate
according to the manufacturer’s guidelines (Gene Therapy Systems). Cells were
then treated with 300 g/ml of hygromycin B (Roche), and resulting single-cell
clones were selected to be expanded in presence of hygromycin B for 2 weeks.
HEK-293 EBNA cells were maintained as serum-free suspension cultures in
Excell-293 medium (JRH Biosciences, Lenexa, KS) in glass spinner flasks (Bellco
Glass Inc., Vineyard, NY) and transiently transfected with polyethyleneimine as
described previously (5).
Northern blotting. Total RNA was isolated using the TRIzol reagent (BRL)
according to the manufacturer’s instructions. RNA was denatured, electropho-
resed on an agarose gel containing formaldehyde, blotted onto nitrocellulose,
and hybridized with 32P-labeled probes according to standard methods.
Western blotting. Twenty microliters of medium, corresponding to 70 g of
total protein, or 10 l of purified scFVs was electrophoresed through 12%
sodium dodecyl sulfate-polyacrylamide gels and transferred to nitrocellulose
membranes by electroblotting. ScFvs were detected by horseradish peroxidase-
conjugated monoclonal anti-c-myc antibody (Invitrogen) and visualized by en-
hanced chemiluminescence (ECL kit; Pierce, Rockford, IL). Alternatively, mem-
branes were incubated with monoclonal anti-c-myc antibody 4A6 (Upstate) and
probed with horseradish peroxidase-labeled anti-mouse IgG1 antibody (Zymed).
Dot and slot blotting. Recombinant PrP at a concentration of 200 ng was
diluted in 100 l of phosphate-buffered saline (PBS) and dotted or slotted onto
a nitrocellulose membrane. The membrane was air dried, blocked with 5% skim
milk in TBST (10 mM Tris-HCl, pH 7.8, 10 mM NaCl, and 0.05% Tween 20), and
incubated with a 1:2 dilution of conditioned medium with TBST for 2 h in a final
volume of 3 ml. After three washing steps (5 min) with TBST, scFv binding was
detected with horseradish peroxidase-conjugated monoclonal anti-His6 antibody
(Invitrogen) and thereafter visualized by enhanced chemiluminescence (ECL kit;
Pierce, Rockford, IL).
Cell blot assay. The cell blot assay was performed as described by Bosque and
Prusiner (6). Cells were transferred to nitrocellulose membrane, treated with
proteinase K, denatured, immunostained with monoclonal antibody 6H4 fol-
lowed by a horseradish peroxidase-conjugated goat anti-mouse IgG1 antibody,
and visualized by enhanced chemiluminescence (ECL kit; Pierce, Rockford, IL).
To assess the extent of transfer of cells to the nitrocellulose membrane, mem-
branes were stained with 0.5 g/ml ethidium bromide for 15 min and photo-
graphed in UV light as described previously (10).
Enrichment and purification of scFvs. Supernatants derived from transiently
transfected HEK-293 cells were enriched for scFvs of clone 4.1 or 4.5 by use of
centrifugal filter devices with an ability to retain molecules above 10 kDa (Ami-
con Ultra; Millipore) or purified by His6 affinity and fast protein liquid chroma-
tography using a nickel-nitrilotriacetic acid (Ni-NTA) kit (QIAGEN) according
to the manufacturer’s description.
Anti-PrP ELISA. Ninety-six-well plates were coated with 5 g/ml mouse re-
combinant PrP23–231 (PrPREC) overnight at 4°C. Plates were washed with PBS
containing 0.1% (vol/vol) Tween 20 (PBST) and blocked with PBST containing
5% bovine serum albumin for 2 h at room temperature (RT). After washing,
plates were incubated with 50 l of serially twofold diluted cell culture super-
natant purified for scFvs or, as technical control, monoclonal antibody POM1 to
mouse PrP. After 2 h at RT, plates were thoroughly washed and probed with a
horseradish peroxidase-conjugated monoclonal anti-c-myc or anti-His antibody
(both from Invitrogen; 1:5000 dilution) for 1 h at RT, except for wells incubated
with POM1, which were probed with horseradish peroxidase-conjugated rabbit
anti-mouse IgG (Zymed; 1:000 dilution). Plates were developed with tetramethyl
benzidine, and optical density was measured at 450 nm. For competition exper-
iments, PrPREC-coated plates were pretreated with serial 10-fold dilutions of
monoclonal antibody POM1 or POM2 (from 2 g to 2 ng/well) for 2 h at RT
before addition of purified scFvs of clone 4.1 or 4.5.
Antibodies. Monoclonal mouse anti-PrP antibodies POM1 and POM2 (both
IgG1) were obtained by immunization of Prnpo/o mice with PrPREC. Splenocytes
were isolated and fused with immortalized myeloma cells according to standard
protocols. PrP-specific clones were selected by ELISA, Western blotting, and
fluorescence-activated cell sorter analysis. POM1 recognizes a mouse PrP
epitope which competes with the 6H4 epitope (amino acids 144 to 152) (23),
while POM2 binds to a linear contiguous N-terminal epitope consisting of resi-
dues 57 to 88 of mouse PrP (M. Polymenidou and A. Aguzzi, unpublished
results).
RESULTS
Expression and secretion of anti-PrP scFv in mammalian
cells. We report the construction of two clones of phages
(termed sc4.1 and sc4.5) displaying the Fv portions of the
heavy and light chains of monoclonal antibody 6H4 (23) as a
single-chain fusion protein (scFv). Antibody 6H4 displays a
high affinity for PrPC and was previously shown to interfere
with the buildup of PrPSc and of prions in vitro (10) and in
transgenic mice (16). The clones were selected by a panning
assay against recombinant full-length PrP (PrPREC) and se-
quenced. The ORFs of clones sc4.1 and sc4.5 were inserted
into the plasmid vector pSecTag2/Hygro (Invitrogen) in order
to allow for eukaryotic expression. pSecTag2/Hygro contains
the CMV promoter, an Ig leader sequence specifying secre-
tion of heterologous proteins, a c-myc tag at the C terminus,
and a hexahistidine tag allowing for detection and purification
through immobilized metal affinity chromatography with nickel-
chelating resin (Fig. 1a). As a positive control for expression
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and secretion in mammalian cells, a clone of pSecTag2/Hygro
containing the open reading frame for human prostate-specific
antigen (PSA) (pSecTag2/Hygro-PSA; Invitrogen) was con-
structed (Fig. 1a).
To assess transcription of pSecTag2/Hygro-sc4.1 and
pSecTag2/Hygro-sc4.5, the human rhabdomyosarcoma cell
line RD-4 (9) was transiently transfected, total RNA was iso-
lated 48 h after transfection, and Northern blotting was per-
formed using a probe spanning the full scFv ORF (Fig. 1b). A
plasmid expressing green fluorescent protein (GFP) under the
control of the CMV promoter (pEGFP-C1) was cotransfected
to monitor the efficiency of transfection.
Next, we assessed translation and secretion of pSecTag2/
Hygro-sc4.1 and pSecTag2/Hygro-sc4.5 in the supernatant of
transiently transfected RD-4 cells by means of Western blot-
ting. Seventy-two hours after transfection, 20 l of conditioned
FIG. 1. Constructs and cells expressing anti-PrP scFv. a: Constructs containing the ORF of anti-PrP scFv (clones 4.1 and 4.5; 957 bp) with VL-
and VH-coding sequences joined by a flexible linker composed of four repeats consisting of four glycine residues and one serine residue [(G4S)4].
Constructs were placed under the control of the CMV enhancer and promoter (627 bp) and fused to an amino-terminal Ig leader sequence and
a carboxy-terminal c-myc/His6 tag. The restriction sites utilized for the cloning and the signal peptide cleavage site are indicated. For a control,
the ORF of PSA (690 bp) was fused to the amino-terminal Ig leader sequence and a carboxy-terminal c-myc/His6 tag. In order to be able to
monitor the efficiency of transfection, the ORF of GFP (731 bp) was put under the control of the CMV enhancer and promoter. b: Transcription
of anti-PrP scFvs (clones sc4.5 and sc4.1 in lanes 1 and 2; GFP as negative control in lane 3) was analyzed by Northern blotting of transiently
transfected RD-4 cells. Lower panel: rRNA bands as loading control. c: Secretion of anti-PrP scFv in supernatants of transiently transfected RD-4
cells, analyzed by Western blotting using an anti-c-myc antibody. Duplicates of each transfection were analyzed in lanes A and B, respectively.
Supernatants derived from cells transfected with PSA (lane 1) or GFP (lane 2) served as positive and negative controls, respectively. A
cross-reacting protein was used as a loading control (ctrl). d: Western blot analysis of anti-PrP scFv protein (clone 4.1A, lane 2) purified by Ni2
affinity chromatography. Supernatants derived from cells transfected with PSA (lane 3) or GFP (lane 1) served as positive and negative controls,
respectively. Markers (left) indicate molecular masses in kDa.
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medium was loaded on a 12% sodium dodecyl sulfate-poly-
acrylamide gel. Correct protein expression of sc4.1 and sc4.5
was indicated by the presence of a protein with a molecular
mass of 36 kDa visualized by antibodies to the fused c-myc
tag (Fig. 1c). Further, Ni2 chelation chromatography resulted
in an enrichment of anti-PrP scFvs (Fig. 1d). These findings
indicate that anti-PrP scFvs were translated and correctly pro-
cessed by the cellular export apparatus, resulting in their se-
cretion into the medium of cultured cells.
Secreted anti-PrP scFvs recognize PrPREC. In order to test
whether secreted anti-PrP scFvs retain their anti-PrP binding
activity, supernatants from transiently transfected RD-4 cells
were analyzed by dot blotting and by slot blotting. Binding of
scFvs was visualized with anti-His antibodies. We found that
conditioned medium derived from sc4.1, but not that derived
from sc4.5 or from any of the negative controls, recognized
PrPREC (Fig. 2a).
If the binding of clone sc4.1 to PrPREC represents a specific
scFv-antigen interaction, it should compete with the binding of
its parental monoclonal antibody 6H4, from which both sc4.1
and sc4.5 were derived. To investigate this question, nitrocel-
lulose membranes were blotted with PrPREC and preincubated
with monoclonal antibody 6H4 (100 ng/ml), which recognizes
residues 144 to 152 of mouse PrPC (23). After such pretreat-
ment of the membrane, sc4.1 no longer reacted to PrPREC. In
contrast, preincubation with an IgG isotype control antibody
(100 ng/ml; Zymed) did not prevent binding (Fig. 2b).
To investigate the specificity and sensitivity of binding to
PrPREC, Ni-NTA-purified scFvs of transiently transfected
HEK-293 cells were analyzed by ELISA on plates coated with
PrPREC and visualized with anti-His antibodies. We detected
strong specific binding of sc4.1, whereas sc4.5 showed no re-
activity (Fig. 2c and d), even when taking into account the fact
that the concentration of sc4.5 was 4-fold lower than that of
sc4.1 (Fig. 2e).
Competition assays further demonstrated that sc4.1 binds a
PrP epitope overlapping that of monoclonal antibody 6H4
(Fig. 2f). Remarkably, sc4.1 was displaced from PrPREC by
6H4 only when the latter holoantibody was added at concen-
trations of 2 g/ml (corresponding to 200 ng/well) or higher
(Fig. 2f). Such concentrations of 6H4 were previously shown to
be sufficient to clear prion infection from cultured chronically
prion-infected N2a cells (10).
To explore their differences in binding to PrPREC, the pri-
mary amino acid sequences of sc4.1 and sc4.5 were analyzed
and found to differ in three amino acids at positions 58, 61, and
293 (Fig. 3). Dissimilarities at residues 58 and 61 were detected
within framework region 1 of the light chain, whereas the
mutation at amino acid 293 was positioned in framework re-
gion 4 of the heavy chain right after the complementarity-
determining region 3. The complementarity-determining re-
gions form loops which contribute to the critical interaction
between the antibody and ligand. Differences in the framework
regions, particularly in close vicinity to complementarity-deter-
mining region 3, which is the main determinant for antigen
binding (4), may destabilize folding (32, 47) and therefore may
explain the lack of PrPC affinity in sc4.5. Therefore, in all
subsequent experiments, clone sc4.5 was operationally re-
garded as of irrelevant specificity and served as a negative control.
Secreted anti-PrP scFvs abolish PrPSc in cocultured prion-
infected N2a/Bos2 cells. In order to test for the prionostatic
effects of anti-PrP scFvs, we cocultured RD-4 cells stably trans-
fected with pSecTag2/Hygro4.1 in the presence of chronically
scrapie-infected N2a/Bos2 neuroblastoma cells (6). Stably
transfected RD-4 cells producing anti-PrP scFvs (Fig. 4a) were
separated by transwell membranes from chronically prion-in-
fected N2a/Bos2 cells (Fig. 4b). Although chronically prion-
infected N2a/Bos2 cells shared their medium with anti-PrP-
scFv-producing cells, no direct cell-cell contact between stably
transfected RD-4 and N2a/Bos2 cells was possible. This exper-
imental design was chosen in order to simulate a paracrine
situation, in which cells expressing scFv may coexist in the
same organ with cells that may be infected with prions but do
not express the antibody.
After 3 weeks of coculturing, including subpassaging of N2a/
Bos2 cells, and change of the transwell membranes with stably
transfected RD-4 cells, the presence of PrPSc in N2a/Bos2 cells
was analyzed by cell blotting (6, 10). We found a drastic re-
duction of PrPSc in prion-infected N2a/Bos2 cells cocultured
with RD-4 cells producing anti-PrP scFvs (sc4.1), whereas no
reduction in PrPSc load was observed in N2a/Bos2 cells cocul-
tured with any of the controls (Fig. 4c). Interestingly, the de-
crease in PrPSc was dependent on the amount of anti-PrP scFv
expression, since clones of RD-4 cells stably transfected with
the same anti-PrP scFvs construct (clone sc4.1) with low ex-
pression were less efficient in clearing PrPSc than clones with
high expression (Fig. 4a to c). N2a/Bos2 cells treated with
anti-PrP scFvs (sc4.1) maintained reduced levels of PrPSc for at
least three further passages (corresponding to 12 days) in the
absence of additional anti-PrP scFv treatment (Fig. 5).
DISCUSSION
The prospect of immunotherapy against prion diseases has
received considerable attention in recent years. Encouraging
results with cell culture systems and with mouse models have
raised hopes that antibodies may prove useful at retarding or
even at blocking prion replication. However, classical vaccina-
tion in wild-type animals appears to be extremely difficult be-
cause of host tolerance to endogenous PrPC (15, 34). We
therefore reasoned that delivery of antibody-like molecules by
gene transfer may be worth investigating, as it might bypass the
tolerance problem described above. We have therefore set out
to employ protein engineering to determine whether it is pos-
sible to express and secrete monovalent single-chain minianti-
bodies (scFvs, which are most frequently produced in prokary-
otic systems) specific to PrP in mammalian cells.
Genetic engineering of antibodies has been utilized in a
variety of ways to address the limitations encountered with
monoclonal antibodies (17). In particular, generation of scFv
moieties with specificities identical to those of their parental
monoclonal antibodies has allowed reduction of neutralizing
and potentially adverse immune responses against holoanti-
bodies and improvement of biodistribution (37). In this re-
spect, the results presented here suggest that secreted forms of
anti-PrP scFv may represent a useful approach to the delivery
of antiprion immunotherapeutic agents.
Administration of anti-PrP scFv presents several distinct ad-
vantages over the use of monoclonal holoantibodies. In par-
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FIG. 2. Specificity and PrP binding properties of scFv fragments. a: Recombinant PrP (PrPREC; 200 ng) was spotted onto nitrocellulose and
incubated with medium derived from RD-4 cells stably expressing anti-PrP scFv (clone 4.5 and clone 4.1), GFP, and PSA. Only supernatant derived
from RD-4 cells transfected with anti-PrP scFv clone 4.1 recognized PrPREC. b: monoclonal antibody 6H4, but not the IgG isotype control,
antagonized binding to PrPREC when administered prior to incubation with sc4.1. c, d: Affinity-purified sc4.1 (filled triangles) resulted in
concentration-dependent binding to PrPREC as assessed by ELISA. In contrast, none of the negative controls or sc4.5 (d) bound PrPC. e: The
relative concentrations of sc4.1 and sc4.5 in the preparations used in panels c and d were estimated by probing serially twofold diluted scFvs with
an antibody to the myc tag upon Western blotting. The negative control (ctrl) was Ni-NTA-purified medium of nontransfected HEK-293 cells.
Numbers on the left indicate molecular masses in kDa. f: Pretreatment of PrPREC-coated ELISA plates with increasing amounts of monoclonal
antibody 6H4 (recognizing mouse PrP144–152) inhibited binding of 4 g purified scFvs (clone 4.1) to PrP
REC (squares), while anti-PrP antibody
POM2 (which recognizes an amino-terminal epitope of PrPC) did not alter PrP reactivity of sc 4.1 (triangles). Solid line, binding of scFvs 4.1 to
PrPREC in the absence of competing antibodies; dashed line, background as determined by the unspecific binding of medium to PrPREC. In panels
c, d, and f, each symbol represents the mean of duplicate measurements, except in panel d, where the mean and standard deviation of triplicates
are depicted. Abscissa, twofold serial dilutions of scFvs (c and d) or amount of competing monoclonal antibody (mab) per well (in ng) (f). Ordinate,
optical density at 450 nm.
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ticular, the delivery of scFvs by genetic transduction in vivo,
e.g., by means of viral vectors, may allow for sustained produc-
tion of scFvs at predefined sites for prolonged periods of time.
This is difficult to obtain by direct systemic administration of
monoclonal antibodies, which are very large molecules and
therefore may present limited bioavailability, and by injection
of recombinant scFvs, which have extremely short half-lives in
blood.
On the other hand, scFv fragments lack all effector domains
of holoantibodies, including Fc and complement binding do-
mains. Since components of the complement system are in-
volved in pathogenesis of scrapie (21, 27), we deemed it par-
ticularly important to assess whether the antiprion biological
activity of scFv fragments is similar to that of full-fledged
holoantibodies. The coculture studies presented here indicate
that this may be the case: effector functions encoded by the
FIG. 3. Nucleotide and corresponding amino acid sequences of the anti-PrP scFv clones 4.1 and 4.5, displaying distinct codon substitutions
(asterisks). The underlined sequence shows the Ig chain leader sequence of clones 4.1 and 4.5 and ends with a signal cleavage site. VL and VH
sequences are joined by a (G4S)4 linker (boldface) and followed by the carboxy terminus with the c-myc as well as the His6 tag (both underlined).
The complementarity-determining regions of the light (CDR-L1-3) and heavy (CDR-H1-3) chains are highlighted in grey (29, 46). The differences
between the VL and VH chain sequence of clones 4.5 and 4.1 are highlighted by asterisks and are likely to be responsible for the difference in
binding to PrP.
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constant domains of antibodies are unnecessary for their an-
tiprion effect on cultured cells.
Intracerebellar or intrahippocampal injection of monoclonal
anti-PrP holoantibodies induces neurotoxicity, whereas injec-
tion of monovalent F(ab)1 fragments prepared from the same
FIG. 4. Anti-PrP scFvs rescue chronically scrapie-infected ScN2a
cells. a: Supernatants of different clones of RD-4 cells stably trans-
fected with respective anti-PrP scFv constructs (either clone 4.1 or 4.5)
were tested by slot immunoblotting for their binding to PrPREC. One
clone with high expression was termed 4.1 high, whereas two clones
with low expression were termed 4.1 low. Clone 4.5 again served as a
negative control. b: Schematic illustration of the transwell model used
for coculturing stably transfected anti-PrP-scFv-producing RD-4 cells
with chronically scrapie prion-infected N2a/Bos2 cells (ScN2a, lower
chamber). The transwell consists of a permeable membrane and allows
diffusion of soluble factors, e.g., anti-PrP scFvs, between RD-4 cells
(cultured on the transwell membrane) and ScN2a cells (cultured on a
glass coverslip in the lower chamber). Thereafter, coverslips with
ScN2a cells were removed and a cell-blot assay was performed. c:
Decrease in PrPSc content in ScN2a cells cocultured with stably trans-
fected RD-4 cells producing large amounts of anti-PrP scFvs (4.1 high,
in duplicate, lanes 1 and 2, upper row). Small amounts of anti-PrP scFv
(4.1 low, lane 3, upper row) or the negative controls (4.5 and PSA;
lanes 4 and 5, upper row) as well as untransfected RD-4 cells (untreat.,
lane 6, upper row) did not alter the PrPSc content in ScN2a cells. The
displayed PrP levels represent PrPSc, since uninfected N2a cells upon
proteinase K digestion displayed only some background signal (N2a,
lane 7, upper row). Ethidium bromide staining demonstrates the pres-
ence of equal amounts of cells per well upon transfer onto nitrocellu-
lose membrane (lower row).
FIG. 5. PrPSc load in anti-PrP-scFv-treated ScN2a cells 12 days
after treatment. a: After 3 weeks of coculturing ScN2a cells with anti-PrP-
scFv-producing RD-4 cells (clone 4.1), ScN2a cells were left in culture
for three further passages (corresponding to 12 days) without further
anti-PrP scFvs treatment. Thereafter, cells were harvested, total pro-
teins were extracted and proteinase K (PK) digested, and Western
blotting for PrPSc with the 6H4 monoclonal antibody was performed
(20 g protein per sample). A strong reduction of PrPSc was observ-
able in ScN2a cells that had previously been exposed to RD-4 cells
producing high levels of anti-PrP scFv (clone 4.1 high, in duplicate;
lanes 3 and 4), in contrast to ScN2a cells exposed to RD-4 cells
producing the 4.5 control clone (lane 1). Lane 2 (N2a) represents the
control for PK digestion on non-prion-infected N2a cells. b: Semiquan-
titative analysis of the residual PrPSc amount in ScN2a cells 12 days
after anti-PrP scFv treatment. Limiting dilutions of the samples (1:1,
1:2, and 1: 4), as indicated, were analyzed by Western blotting, and the
respective bands were assessed densitometrically (Molecular Dynam-
ics system); values are calculated as the mean  standard error of the
mean of the average band density for each dilution. c: Bar graph
displaying the densitometric differences in the PrPSc load in anti-PrP-
scFv-treated ScN2a cells (as shown in panels a and b). ScN2a cells
treated with anti-PrP scFvs (clone 4.1) maintained a 90% reduction in
the PrPSc load in ScN2a cells 12 days after anti-PrP-scFv treatment
compared to ScN2a cells cocultured with RD-4 cells stably transfected
with the control clone 4.5. Statistical significance (P  0.005) was
assessed by Student’s t test. , proteinase K digestion.
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monoclonal antibodies was innocuous, suggesting that anti-
body-induced cross-linking of PrPC may be toxic (40). How-
ever, if toxicity is inherent to the bivalent character of mono-
clonal IgG holoantibodies, as the results mentioned above
appear to suggest, one would expect that anti-PrP scFvs, which
are monovalent and therefore cannot cross-link PrPC, should
be safer than bivalent full-fledged antibodies.
Curing scrapie-infected neuroblastoma cells is likely to be
easier than eradicating prions from infected organisms. The
bewildering variety of chemicals that appear to suppress prion
replication in N2a cells bears witness to the suspicion that
activation of a variety of pathways may impair the ability of
N2a cells to support prion replication (1). For this reason, it
will be important to confirm the efficacy of any proposed scFv-
based immunotherapy in animal models. The comparatively
small size of the cDNA that encodes for the scFv described
here (957 base pairs) makes it easy to efficiently package it into
a variety of viral vectors. Further studies will need to address
the feasibility and scalability of this approach. For basic studies
of prion replication, transduction of eukaryotic cells with anti-
PrP scFv fragments may represent a useful tool to suppress
prion replication in localized tissue compartments or in specific
cell types without interfering with Prnp transcription. With
respect to translational research, mammalian cells expressing
anti-PrP scFvs may present a therapeutic tool to interfere with
prion replication while avoiding problems encountered with
classical active or passive PrP immunization.
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